These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30560685)

  • 1. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
    Soria J; Mugruza R; Levine M; León SR; Arévalo J; Ticona E; Beck IA; Frenkel LM
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):150-154. PubMed ID: 30560685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
    Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
    Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru.
    Soria J; Bull M; Mitchell C; La Rosa A; Dross S; Kraft K; Coombs R; Ticona E; Frenkel L
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):333-8. PubMed ID: 21819256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.
    Chung MH; Beck IA; Dross S; Tapia K; Kiarie JN; Richardson BA; Overbaugh J; Sakr SR; John-Stewart GC; Frenkel LM
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):246-53. PubMed ID: 25140907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
    Panpradist N; Beck IA; Ruth PS; Ávila-Ríos S; García-Morales C; Soto-Nava M; Tapia-Trejo D; Matías-Florentino M; Paz-Juarez HE; Del Arenal-Sanchez S; Reyes-Terán G; Lutz BR; Frenkel LM
    AIDS; 2020 Jul; 34(9):1331-1338. PubMed ID: 32205723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.
    Beck IA; Levine M; McGrath CJ; Bii S; Milne RS; Kingoo JM; So I; Andersen N; Dross S; Coombs RW; Kiarie J; Chohan B; Sakr SR; Chung MH; Frenkel LM
    EClinicalMedicine; 2020 Jan; 18():100239. PubMed ID: 31956856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru.
    Trebelcock WL; Lama JR; Duerr A; Sanchez H; Cabello R; Gilada T; Segura P; Reisner SL; Mayer KH; Mullins J; Bender Ignacio RA
    J Int AIDS Soc; 2019 Nov; 22(11):e25411. PubMed ID: 31773888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi.
    Neuhann F; de Forest A; Heger E; Nhlema A; Scheller C; Kaiser R; Steffen HM; Tweya H; Fätkenheuer G; Phiri S
    AIDS Res Ther; 2020 May; 17(1):22. PubMed ID: 32434561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.
    Milne RS; Silverman RA; Beck IA; Mckernan-Mullin J; Deng W; Sibley TR; Dross S; Kiarie JN; Sakr SR; Coombs RW; Chung MH; Frenkel LM
    AIDS; 2019 May; 33(6):941-951. PubMed ID: 30946148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.
    Silverman RA; Beck IA; Kiptinness C; Levine M; Milne R; McGrath CJ; Bii S; Richardson BA; John-Stewart G; Chohan B; Sakr SR; Kiarie JN; Frenkel LM; Chung MH
    J Infect Dis; 2017 Dec; 216(12):1569-1578. PubMed ID: 29040633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.
    Orrell C; Walensky RP; Losina E; Pitt J; Freedberg KA; Wood R
    Antivir Ther; 2009; 14(4):523-31. PubMed ID: 19578237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.
    Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G
    J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].
    Yalçınkaya T; Köse S
    Mikrobiyol Bul; 2014 Oct; 48(4):585-95. PubMed ID: 25492654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
    Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
    BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines.
    Kebe K; Thiam M; Diagne Gueye NR; Diop H; Dia A; Signate Sy H; Charpentier C; Belec L; Mboup S; Toure Kane C
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):242-9. PubMed ID: 22860571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Jittamala P; Puthanakit T; Chaiinseeard S; Sirisanthana V
    Pediatr Infect Dis J; 2009 Sep; 28(9):826-30. PubMed ID: 19654564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China.
    Wang Z; Zhang M; Zhang R; Liu L; Shen Y; Wang J; Lu H
    BMC Infect Dis; 2019 Apr; 19(1):313. PubMed ID: 30961560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
    Mendoza Y; Castillo Mewa J; Martínez AA; Zaldívar Y; Sosa N; Arteaga G; Armién B; Bautista CT; García-Morales C; Tapia-Trejo D; Ávila-Ríos S; Reyes-Terán G; Bello G; Pascale JM
    PLoS One; 2016; 11(4):e0154317. PubMed ID: 27119150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon.
    Fokam J; Takou D; Teto G; Nforbih SE; Kome OP; Santoro MM; Ngoufack ES; Eyongetah M; Palmer D; Fokunang ET; Fokunang CN; Colizzi V; Perno CF; Ndjolo A
    PLoS One; 2020; 15(7):e0235958. PubMed ID: 32692778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis.
    Rath BA; von Kleist M; Castillo ME; Kolevic L; Caballero P; Soto-Castellares G; Amedee AM; Robinson JE; Katzenstein DK; Van Dyke RB; Oberhelman RA
    BMC Infect Dis; 2013 Jan; 13():1. PubMed ID: 23280237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.